Carlsmed (CARL) Fundamental Analysis: Revenue, Earnings & Valuation

1.15 / 10

Underperform

Fundamental analysis rates CARL as Underperform with a 1.1/10 score, indicating weak health. Cash‑up and diluted ROE are modest positives, while cash‑MV, profit‑MV, ROE, ROA and profit margins are negative, reflecting constrained earnings and asset quality.

Analysis Checks(2/10)

ROA (%)

Value-32.57

Score1/3

Weight5.37%

1M Return-1.19%

Annualized return on equity (%)

Value-48.56

Score1/3

Weight8.88%

1M Return-2.02%

Profit-MV

Value0.68

Score1/3

Weight22.57%

1M Return-5.93%

Cash-UP

Value-0.16

Score2/3

Weight16.35%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-32.57

Score1/3

Weight5.37%

1M Return-1.19%

ROE (diluted) (%)

Value-30.56

Score2/3

Weight-5.81%

1M Return1.11%

Asset-MV

Value-0.55

Score0/3

Weight14.37%

1M Return-3.34%

ROE (%)

Value-48.56

Score1/3

Weight8.88%

1M Return-2.02%

Cash-MV

Value0.03

Score1/3

Weight14.10%

1M Return-3.56%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight9.92%

1M Return-2.37%

Is CARL fundamentally strong?

CARL scores 1.15/10 on fundamentals and holds a Premium valuation at present. Backed by its -48.56% ROE, -58.67% net margin, -9.01 P/E ratio, 2.76 P/B ratio, and 65.30% earnings growth, these metrics solidify its Underperform investment rating.